TürkiyeDiagnosis and screening
In Wilson disease, a diagnostic delay of more than one year was linked to a worse course
A study from Kayseri City Hospital examined diagnostic delay in Wilson disease.
Inborn errors of metabolism
An inherited disease in which copper builds up in the body, mostly in the liver, brain and eyes. Symptoms often begin in adolescence. Liver, nervous system and mental health problems may occur.
Not part of the panel of Türkiye's National Newborn Screening Programme (heel-prick test). Source
This page is translated from the Turkish original.
This disease is followed through the “Inborn errors of metabolism” group.
The body cannot get rid of excess copper. Normally the liver removes excess copper through bile. In this disease, copper builds up mostly in the liver, brain and eyes. This build-up damages the tissues.
Symptoms often begin between 6-45 years of age, most often in adolescence. They can be very different, even within the same family.
The diagnosis is made based on the symptoms and blood and urine tests. A protein that carries copper in the blood is low. Copper in the urine is found to be high. If needed, a sample is taken from the liver and a genetic test is done.
There is no cure; the aim of treatment is to reduce the copper in the body. For this, medicines that bind copper, zinc and a low-copper diet are used. With severe liver damage, a liver transplant may be needed. With treatment started early and kept up regularly, most people can live a good life. The doctor who follows the disease decides which treatment is suitable.
The disease is passed on through recessive inheritance. For a couple who are both carriers, the chance of having an affected child is 1 in 4 in each pregnancy. Some patients are found through family screening. Genetic counselling is recommended for brothers and sisters.
Source: MedlinePlus Genetics — Wilson disease · Orphanet — Wilson disease
These facts are taken from Orphanet and MedlinePlus records (last checked: October 7, 2026). Frequency values are approximate ranges.
Non-profit patient and family organizations in Türkiye working on this disease or disease group. Links are for information; Doktorclub is not affiliated with these organizations and does not endorse them.
We could not find a patient association specific to this disease.
For all rare diseases: Nadir Hastalıklar Federasyonu
Doktorclub does not diagnose, recommend treatments or refer you to hospitals or doctors. These pages are meant to help you talk with your doctor.
TürkiyeDiagnosis and screening
A study from Kayseri City Hospital examined diagnostic delay in Wilson disease.
TürkiyeResearch and clinical trials
Istanbul Faculty of Medicine studied 54 women with Wilson disease.
A clinical trial is a regulated study that tests whether a new treatment is safe and whether it works, in patients who volunteer. Most trials look for a certain age, genetic change and health condition. Taking part is voluntary.
Questions you can ask your doctor
ClinicalTrials.gov lists 14 active interventional studies for this disease. 7 are recruiting now; none has a site in Türkiye. Last checked: October 7, 2026.
Selected records (studies with a site in Türkiye first):
Late stage: the effect is being compared in a large group · Phase 3 · investigational (experimental)RecruitingNCT07465718
Middle stage: the effect is being tested in a small group · Phase 1 / Phase 2 · investigational (experimental)RecruitingNCT07748403
Early stage: safety and dose are being tested · Early phase 1 · investigational (experimental)RecruitingNCT06650319
Early stage: safety and dose are being tested · Early phase 1 · investigational (experimental)RecruitingNCT07240896
Middle stage: the effect is being tested in a small group · Phase 1 / Phase 2 · investigational (experimental)Active, not recruitingNCT04884815
See all studies on ClinicalTrials.gov · Joining clinical trials
EUNew treatments and approvals
In Europe, leriglitazone, taken by mouth, was authorized for cerebral adrenoleukodystrophy.
USANew treatments and approvals
Through the accelerated pathway, the FDA has approved pariglasgene brecaparvovec for glycogen storage disease type Ia.
EuropeResearch and clinical trials
A total of 58 patients from 34 centers in seven European countries were followed.
These codes identify the disease in international classifications and databases. They can help when you talk with your doctor or look for reliable sources.
Orphanet code: ORPHA:905 · ICD-11 5C64.00
Codes checked against WHO ICD-11 and Orphanet on October 6, 2026.
This page provides general information and does not replace diagnosis or treatment. Talk to your doctor about symptoms, diagnosis and treatment.